Lv1
70 积分 2025-07-12 加入
Combined Impact of Triglyceride-Glucose Index and Alanine Aminotransferase on Steatotic Liver Disease and Subtypes
2个月前
已完结
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs
4个月前
已完结
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
5个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
7个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
7个月前
已完结
Clinical Trial Landscape in NASH
7个月前
已完结
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
7个月前
已完结
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
7个月前
已完结
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
7个月前
已完结
Metabolic dysfunction-associated steatotic liver disease in adults
7个月前
已完结
皖公网安备34019202002308
